ALPN Alpine Immune Sciences Inc.

9.8
+0.21  (+2%)
Previous Close 9.59
Open 9.71
52 Week Low 7.21
52 Week High 16.37
Market Cap $234,365,814
Shares 23,914,879
Float 10,072,665
Enterprise Value $170,490,790
Volume 126,941
Av. Daily Volume 67,387
Stock charts supplied by TradingView

Drug Pipeline

Drug Stage Notes
ALPN-202 KEYTRUDA (pembrolizumab) - NEON-2
Solid Tumors
Phase 1
Phase 1
Phase 1 dosing has commenced - June 30, 2021.
ALPN-101
Systemic Lupus Erythematosus (SLE
Phase 2
Phase 2
Phase 2 initiation of dosing announced June 24, 2021.
ALPN-202 (NEON-1)
Advanced Malignancies
Phase 1
Phase 1
Phase 1 data presented at ASCO June 4, 2021. 61% (14 of 23) showed clinical benefit (stable disease or better).
ALPN-101
Graft Vs Host Disease
Phase 1/2
Phase 1/2
Phase 1b/2 trial is open for enrolment - noted March 30, 2020.
N91115
Cystic Fibrosis - one copy of the F508del mutation and a second mutation that results in a gating defect in the CFTR protein
Phase 2
Phase 2
Phase 2 data released February 24, 2017 - primary endpoint not met.

Latest News

  1. Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced it has entered into a definitive securities purchase agreement for the sale of common stock and prefunded warrants, as described below, in a private placement with certain institutional and other accredited investors for gross proceeds to Alpine of approximately $91 million, before deducting offering expenses. The private placement is being led by Frazier Life Sciences Public Fund with participation from Decheng Capital, BVF Partners, TCG X, Avidity Partners, OrbiMed, Omega Fund, and Logos Capital, among others.

    "As a long-term backer of Alpine…

    Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced it has entered into a definitive securities purchase agreement for the sale of common stock and prefunded warrants, as described below, in a private placement with certain institutional and other accredited investors for gross proceeds to Alpine of approximately $91 million, before deducting offering expenses. The private placement is being led by Frazier Life Sciences Public Fund with participation from Decheng Capital, BVF Partners, TCG X, Avidity Partners, OrbiMed, Omega Fund, and Logos Capital, among others.

    "As a long-term backer of Alpine, we are impressed by the company's progress and their emergence as a leader in both immunology and immuno-oncology," said James Topper, M.D., Ph.D, Managing General Partner of Frazier's Life Sciences team. "This financing will help the company to pursue a focused and rapid development plan for ALPN-303, a potentially best-in-class inhibitor of the BAFF and APRIL pathways, and will also support the ongoing development of ALPN-202 as it enters monotherapy expansion cohorts next year and expands its development efforts in combination with Keytruda. We are pleased to lead this syndicate of strong investors and look forward to supporting the company in this next phase of growth."

    Pursuant to the terms of the securities purchase agreement, at the closing of the private placement, Alpine will issue approximately 6.5 million shares of common stock and approximately 3.2 million prefunded warrants to purchase the same number of shares of common stock. Both the common stock and prefunded warrants will be sold at a price of $9.40 per share or prefunded warrant, respectively. The prefunded warrants will have a per share exercise price of $0.001 and will be exercisable at any time on or after the closing date. The price of the common stock and prefunded warrants is at a 4.4% premium to the closing price of $9.00 per share of Alpine's common stock on the Nasdaq Global Market on September 14, 2021.

    The private placement is expected to close on or about September 17, 2021, subject to the satisfaction of customary closing conditions. Additional details regarding the private placement will be included in a Form 8-K to be filed by Alpine with the Securities and Exchange Commission ("SEC").

    Alpine intends to use the net proceeds to support the expansion of its pipeline, including the development of ALPN-303 in lupus and other B cell-mediated inflammatory diseases. In addition, net proceeds will be used to support the further clinical development of ALPN-202 as well as Alpine's discovery programs and general corporate purposes.

    In connection with the entry into the securities purchase agreement, an affiliate of Frazier Life Sciences Public Fund entered into an exchange agreement with Alpine, pursuant to which Alpine will exchange an aggregate of 1.2 million shares of common stock currently held by the affiliate of Frazier Life Sciences Public Fund for prefunded warrants to purchase an aggregate of 1.2 million shares of common stock, which prefunded warrants have identical terms to the prefunded warrants sold pursuant to the securities purchase agreement. After giving effect to the exchange of 1.2 million shares of common stock and the issuance of the approximately 6.5 million shares pursuant to the securities purchase agreement, the number of shares of Alpine's outstanding common stock immediately after this offering would be approximately 29.2 million as of July 30, 2021. The closing of the exchange is subject to customary closing conditions and is contingent upon and will occur immediately following the closing of the private placement.

    The securities being sold in the private placement have not been registered under the Securities Act of 1933, as amended, or state securities laws and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements. Alpine has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable in connection with the private placement and upon exercise of the prefunded warrants.

    This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

    About Alpine Immune Sciences, Inc.

    Alpine Immune Sciences, Inc. is committed to leading a new wave of immune therapeutics. With world-class research and development capabilities, a highly productive scientific platform, and a proven management team, Alpine is seeking to create first- or best-in-class multifunctional immunotherapies via unique protein engineering technologies to improve patients' lives. Alpine has entered into strategic collaborations with leading global biopharmaceutical companies and has a diverse pipeline of clinical and preclinical candidates in development. For more information, visit www.alpineimmunesciences.com. Follow @AlpineImmuneSci on Twitter and LinkedIn.

    About Frazier Healthcare Partners

    Founded in 1991, Frazier Healthcare Partners is a leading provider of private equity capital to healthcare companies. With more than $6.2 billion total capital raised, Frazier has invested in more than 200 companies with transaction types ranging from buyouts of profitable healthcare companies to venture capital and company creation. Frazier has a philosophy of partnering with strong management teams while leveraging its internal operating resources and network to build exceptional companies. Frazier has offices in Seattle, Wash., and Menlo Park, Calif., and invests broadly across the U.S., Canada and Europe. For more information about Frazier Healthcare Partners, please visit www.frazierhealthcare.com.

    Forward-Looking Statements

    This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact, and include statements regarding Alpine's platform technology, potential therapies, clinical development plans and the timing thereof, the receipt of potential milestones under Alpine's collaborations, the anticipated closing of the private placement and the exchange and the timing thereof, and the expected receipt and use of proceeds from the private placement. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "intend," and other similar expressions among others. These forward-looking statements are based on current assumptions that involve risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: Alpine's development programs may not advance into the clinic, succeed in the clinic or result in approved products on a timely or cost-effective basis or at all; Alpine's assumptions regarding its planned expenditures and sufficiency of its cash to fund operations may be incorrect; Alpine may not achieve additional milestone payments pursuant to its collaborations; the impact of competition; adverse conditions in the general domestic and global economic markets; as well as the other risks identified in Alpine's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof and Alpine undertakes no obligation to update forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements.

    The Alpine logo is a registered trademark or trademark of Alpine Immune Sciences, Inc. in various jurisdictions.

    View Full Article Hide Full Article
  2. Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced that members of its management team will present at the following investor conferences in September 2021:

    H.C. Wainwright 23rd Annual Global Investment Conference
    Date: Monday, September 13, 2021
    Time: Available on demand beginning 7:00 a.m. ET/4:00 a.m. PT
    Event: Company Presentation

    Oppenheimer Fall Healthcare Summit
    Date: Monday, September 20, 2021
    Time: 2:55 p.m. ET/11:55 a.m. PT
    Event: Fireside Chat

    Cantor Global Healthcare Conference
    Date: Wednesday, September 29, 2021
    Time: 2:00 p.m. ET/11:00 a.m. PT
    Event: Company Presentation

    Webcasts…

    Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced that members of its management team will present at the following investor conferences in September 2021:

    H.C. Wainwright 23rd Annual Global Investment Conference

    Date: Monday, September 13, 2021

    Time: Available on demand beginning 7:00 a.m. ET/4:00 a.m. PT

    Event: Company Presentation

    Oppenheimer Fall Healthcare Summit

    Date: Monday, September 20, 2021

    Time: 2:55 p.m. ET/11:55 a.m. PT

    Event: Fireside Chat

    Cantor Global Healthcare Conference

    Date: Wednesday, September 29, 2021

    Time: 2:00 p.m. ET/11:00 a.m. PT

    Event: Company Presentation

    Webcasts of the H.C. Wainwright, Oppenheimer, and Cantor presentations will be available online in the investor relations section of the company's website at https://ir.alpineimmunesciences.com/events. A replay of the presentations will be available on the company website for 90 days following the webcast.

    About Alpine Immune Sciences, Inc.

    Alpine Immune Sciences, Inc. is committed to leading a new wave of immune therapeutics. With world-class research and development capabilities, a highly productive scientific platform, and a proven management team, Alpine is seeking to create first- or best-in-class multifunctional immunotherapies via unique protein engineering technologies to improve patients' lives. Alpine has entered into strategic collaborations with leading global biopharmaceutical companies and has a diverse pipeline of clinical and preclinical candidates in development. For more information, visit www.alpineimmunesciences.com. Follow @AlpineImmuneSci on Twitter and LinkedIn.

    View Full Article Hide Full Article
  3. - Conference call and webcast today at 4:30 p.m. ET -

    Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today provided a corporate update and reported financial results for the second quarter ended June 30, 2021.

    "We have had a highly productive second quarter with substantial progress made across our portfolio highlighted by the initiation of Synergy, our international Phase 2 trial of ALPN-101, or acazicolcept, in lupus patients, the achievement of $45 million in development milestones as part of our AbbVie agreement, and the first presentation of clinical data from ALPN-202 highlighting the potential differentiation…

    - Conference call and webcast today at 4:30 p.m. ET -

    Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today provided a corporate update and reported financial results for the second quarter ended June 30, 2021.

    "We have had a highly productive second quarter with substantial progress made across our portfolio highlighted by the initiation of Synergy, our international Phase 2 trial of ALPN-101, or acazicolcept, in lupus patients, the achievement of $45 million in development milestones as part of our AbbVie agreement, and the first presentation of clinical data from ALPN-202 highlighting the potential differentiation of safely agonizing CD28. Alpine has evolved into a global development company with clinical programs in both Immunology and Oncology and two strong pharmaceutical partners in AbbVie and Merck," said Mitchell H. Gold, M.D., Executive Chairman and Chief Executive Officer of Alpine. "Looking forward, we plan to initiate our Phase 1 study for ALPN-303 by the fourth quarter and look forward to providing other updates as we progress on all our clinical studies."

    Second Quarter 2021 and Recent Corporate and Clinical Updates

    • Acazicolcept: Dual CD28/ICOS inhibitor
      • Initiated Synergy, an international, double-blind placebo-controlled Phase 2 study of acazicolcept in patients with Systemic Lupus Erythematosus (SLE).
      • Achieved $45 million in pre-option exercise development milestones as part of the 2020 Option and License Agreement with AbbVie, with the potential of an additional $30 million in pre-option exercise development milestones.
    • ALPN-202: Conditional CD28 costimulator and dual checkpoint inhibitor
      • Presented initial dose escalation experience with ALPN-202 monotherapy in the NEON-1 clinical trial at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. ALPN-202 was well-tolerated to date, with evidence of peripheral T cell modulation consistent with CD28 agonism, and clinical benefit observed in the majority of participants, despite the population consisting of heavily pre-treated, advanced tumor types traditionally considered unresponsive to immunotherapies.
      • Entered a clinical trial collaboration and supply agreement with Merck and initiated enrollment in NEON-2, a dose escalation and expansion study to evaluate the safety and efficacy of ALPN-202 in combination with KEYTRUDA® (pembrolizumab).
    • ALPN-303: Dual APRIL/BAFF inhibitor
      • Presented an oral abstract at the 2021 European Alliance of Associations for Rheumatology (EULAR) virtual meeting demonstrating superior preclinical activity of ALPN-303 compared to multiple comparators, including wild-type TACI-Fc fusion proteins.
      • Targeting completion of activities to support initiation of a Phase 1 healthy volunteer study with ALPN-303 in the fourth quarter of this year.
    • General Corporate
      • Appointed Zelanna Goldberg, M.D., M.A.S. as Chief Medical Officer: Dr. Goldberg brings over 20 years of industry and clinical practice experience, including strategic and/or operational responsibility for multiple therapeutic products. Most recently Dr. Goldberg was Senior Vice President of Clinical Science at Iovance Biotherapeutics.
      • Added to the Russel 3000® Index.

    Second Quarter 2021 Financial Results

    As of June 30, 2021, we had cash, cash equivalents, restricted cash, and investments totaling $100.4 million, which does not include the $45.0 million in achieved milestones from the AbbVie collaboration expected to be received in the third quarter. We recorded net losses of $11.0 million and $9.9 million for the quarters ended June 30, 2021 and 2020, respectively.

    Collaboration revenue for the quarter ended June 30, 2021 was $7.2 million compared to $0.7 million for the quarter ended June 30, 2020. The increase was primarily attributable to the revenue recognized under our AbbVie Agreement.

    Research and development expenses for the quarter ended June 30, 2021 were $14.6 million compared to $7.1 million for the quarter ended June 30, 2020. The increase was primarily attributable to contract manufacturing and process development of our product candidates, personnel-related expenses, clinical trial activities, and direct research activities.

    General and administrative expenses for the quarter ended June 30, 2021 were $3.3 million compared to $3.3 million for the quarter ended June 30, 2020. While the costs remained relatively constant, decreases in professional and legal services were partially offset by increases in personnel-related expenses to support the growth and expansion of our business.

    Alpine expects that its current cash resources, combined with the $45 million in achieved milestones and the potential additional $30 million in pre-option exercise milestones payable under its option and license agreement with AbbVie, for the development and commercialization of acazicolcept, are sufficient to fund Alpine's planned operations through 2023.

    Second Quarter 2021 Conference Call and Webcast Details

    Alpine will host a conference call and live webcast to discuss the second quarter performance today, August 10, 2021 at 4:30 p.m. ET/1:30 p.m. PT.

    To access the live call by phone, dial (800) 816-3005 (domestic) or (857) 770-0069 (international) and reference conference ID: 8145346. A live webcast of the presentation will be available online in the investor relations section of the company's website at https://ir.alpineimmunesciences.com/events. A replay of the presentation will be available on the company website for 90 days following the webcast.

    About Alpine Immune Sciences, Inc.

    Alpine Immune Sciences, Inc. is committed to leading a new wave of immune therapeutics. With world-class research and development capabilities, a highly productive scientific platform, and a proven management team, Alpine is seeking to create first- or best-in-class multifunctional immunotherapies via unique protein engineering technologies to improve patients' lives. Alpine has entered into strategic collaborations with leading global biopharmaceutical companies and has a diverse pipeline of clinical and preclinical candidates in development. For more information, visit www.alpineimmunesciences.com. Follow @AlpineImmuneSci on Twitter and LinkedIn.

    Forward-Looking Statements

    This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include statements regarding our platform technology and potential therapies, the timing of and results from clinical trials and preclinical development activities, clinical and regulatory objectives and the timing thereof, expectations regarding the sufficiency of cash combined with the $45 million in achieved and the potential additional $30 million in pre-option exercise milestones payable under our option and license agreement with AbbVie to fund operations through 2023, the potential efficacy, safety profile, future development plans, addressable market, regulatory success, and commercial potential of our product candidates, our ability to achieve additional milestones in our collaboration with AbbVie, the progress and potential of our other ongoing development programs, the timing of our public presentations and potential publication of future clinical data, the efficacy of our clinical trial designs, anticipated enrollment in our clinical trials and the timing thereof, expectations regarding our ongoing collaborations, and our ability to successfully develop and achieve milestones in our development programs. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions and include words such as "may," "will," "should," "would," "expect," "plan," "intend," and other similar expressions, among others. These forward-looking statements are based on current assumptions that involve risks, uncertainties, and other factors that may cause actual results, events, or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: the impact of the COVID-19 pandemic on our business, research and clinical development plans and timelines and results of operations, including the impact on our clinical trial sites, collaborators, and contractors who act for or on our behalf, may be more severe and prolonged than currently anticipated; clinical trials may not demonstrate safety and efficacy of any of our product candidates; our ongoing discovery and preclinical efforts may not yield additional product candidates; our discovery-stage and preclinical programs may not advance into the clinic or result in approved products; any of our product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; we may not achieve additional milestones in our proprietary or partnered programs; the impact of competition; adverse conditions in the general domestic and global economic markets; as well as the other risks identified in our filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof and we undertake no obligation to update forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements.

    "SIP" and "TIP," and the Alpine logo are registered trademarks or trademarks of Alpine Immune Sciences, Inc. in various jurisdictions.

    Alpine Immune Sciences, Inc.

     

     

     

     

    Selected Consolidated Balance Sheet Data

     

     

     

     

    (In thousands)

     

     

     

     

     

     

    June 30, 2021

     

    December 31, 2020

     

     

    (unaudited)

     

     

    Cash and cash equivalents

     

    $

    18,813

     

     

    $

    34,959

     

    Short-term investments

     

    72,247

     

     

    70,622

     

    Total current assets

     

    139,736

     

     

    107,101

     

    Long-term investments

     

    9,120

     

     

    25,549

     

    Total assets

     

    159,818

     

     

    144,090

     

    Total current liabilities

     

    60,246

     

     

    41,167

     

    Total stockholders' equity

     

    43,831

     

     

    62,158

     

    Total liabilities and stockholders' equity

     

    159,818

     

     

    144,090

     

     

    Consolidated Statement of Operations and

    Comprehensive Income (Loss) Data

     

     

     

     

     

     

     

    (In thousands, except share and per share amounts)

    Three Months Ended June 30,

     

    Six Months Ended June 30,

     

    2021

     

     

    2020

     

     

    2021

     

     

    2020

     

     

    (unaudited)

    Collaboration revenue

    $

    7,193

     

     

     

    $

    688

     

     

     

    $

    10,397

     

     

     

    $

    1,779

     

     

    Operating expenses:

     

     

     

     

     

     

     

    Research and development

    14,634

     

     

     

    7,096

     

     

     

    25,071

     

     

     

    11,974

     

     

    General and administrative

    3,290

     

     

     

    3,344

     

     

     

    6,546

     

     

     

    5,122

     

     

    Total operating expenses

    17,924

     

     

     

    10,440

     

     

     

    31,617

     

     

     

    17,096

     

     

    Loss from operations

    (10,731

    )

     

     

    (9,752

    )

     

     

    (21,220

    )

     

     

    (15,317

    )

     

    Other income (expense):

     

     

     

     

     

     

     

    Interest expense

    (218

    )

     

     

    (226

    )

     

     

    (435

    )

     

     

    (346

    )

     

    Interest income

    51

     

     

     

    44

     

     

     

    114

     

     

     

    196

     

     

    Loss before taxes

    (10,898

    )

     

     

    (9,934

    )

     

     

    (21,541

    )

     

     

    (15,467

    )

     

    Income tax (expense) benefit

    (131

    )

     

     

    6

     

     

     

    (131

    )

     

     

    6

     

     

    Net loss

    $

    (11,029

    )

     

     

    $

    (9,928

    )

     

     

    $

    (21,672

    )

     

     

    $

    (15,461

    )

     

    Comprehensive income (loss):

     

     

     

     

     

     

     

    Unrealized gain (loss) on investments

    21

     

     

     

    (1

    )

     

     

    16

     

     

     

    (16

    )

     

    Unrealized (loss) gain on foreign currency translation

    (9

    )

     

     

    64

     

     

     

    (24

    )

     

     

    (49

    )

     

    Comprehensive loss

    $

    (11,017

    )

     

     

    $

    (9,865

    )

     

     

    $

    (21,680

    )

     

     

    $

    (15,526

    )

     

    Weighted-average shares used to compute basic and diluted net loss per share

    23,908,516

     

     

     

    18,588,993

     

     

     

    23,888,173

     

     

     

    18,588,442

     

     

    Basic and diluted net loss per share

    $

    (0.46

    )

     

     

    $

    (0.53

    )

     

     

    $

    (0.91

    )

     

     

    $

    (0.83

    )

     

     

    View Full Article Hide Full Article
  4. Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the company will release second quarter 2021 financial results on Tuesday, August 10, 2021 after the close of market. Alpine will host a corresponding conference call and live webcast at 4:30 p.m. ET/1:30 p.m. PT on the same day to discuss the results and provide a corporate update.

    Company management will also present at the following upcoming investor events and conferences:

    • Bernstein CD28 Day
      Presentation: Monday, August 9, 12:15 p.m. ET (9:15 a.m. PT)
      Following the presentation, the presented materials from the Bernstein CD28 Day will be…

    Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the company will release second quarter 2021 financial results on Tuesday, August 10, 2021 after the close of market. Alpine will host a corresponding conference call and live webcast at 4:30 p.m. ET/1:30 p.m. PT on the same day to discuss the results and provide a corporate update.

    Company management will also present at the following upcoming investor events and conferences:

    • Bernstein CD28 Day

      Presentation: Monday, August 9, 12:15 p.m. ET (9:15 a.m. PT)

      Following the presentation, the presented materials from the Bernstein CD28 Day will be available under "Events & Presentations" portion of the Investors section of the company website.
    • 2021 Wedbush PacGrow Healthcare Virtual Conference

      For Your IOnly - Progress, Challenges in Immuno-Oncology Panel: Wednesday, August 11, 12:35 p.m. ET (9:35 a.m. PT)

    Second Quarter 2021 Financial Results Conference Call and Webcast Details

    To access the live call by phone, dial (800) 816-3005 (domestic) or (857) 770-0069 (international) and reference conference ID: 8145346. A live webcast of the presentation will be available online in the investor relations section of the company's website at https://ir.alpineimmunesciences.com/events. A replay of the presentation will be available on the company website for 90 days following the webcast.

    About Alpine Immune Sciences, Inc.

    Alpine Immune Sciences, Inc. is committed to leading a new wave of immune therapeutics. With world-class research and development capabilities, a highly productive scientific platform, and a proven management team, Alpine is seeking to create first- or best-in-class multifunctional immunotherapies via unique protein engineering technologies to improve patients' lives. Alpine has entered into strategic collaborations with leading global biopharmaceutical companies and has a diverse pipeline of clinical and preclinical candidates in development. For more information, visit www.alpineimmunesciences.com. Follow @AlpineImmuneSci on Twitter and LinkedIn.

    Source: Alpine Immune Sciences Inc.

    View Full Article Hide Full Article
  5. - First Patient Dosed in NEON-2 Clinical Trial -

    Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, announced today a clinical trial collaboration and supply agreement with Merck. This collaboration will evaluate the safety and efficacy of Alpine's ALPN-202, a first-in-class conditional CD28 costimulator and dual checkpoint inhibitor, in combination with Merck's anti-PD-1 therapy KEYTRUDA® (pembrolizumab), the first anti-PD-1 therapy approved in the United States. The clinical trial, NEON-2, began dosing study participants in June 2021.

    "We are extremely pleased to collaborate with Merck, one of the world's…

    - First Patient Dosed in NEON-2 Clinical Trial -

    Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, announced today a clinical trial collaboration and supply agreement with Merck. This collaboration will evaluate the safety and efficacy of Alpine's ALPN-202, a first-in-class conditional CD28 costimulator and dual checkpoint inhibitor, in combination with Merck's anti-PD-1 therapy KEYTRUDA® (pembrolizumab), the first anti-PD-1 therapy approved in the United States. The clinical trial, NEON-2, began dosing study participants in June 2021.

    "We are extremely pleased to collaborate with Merck, one of the world's leading immuno-oncology companies," said Stanford Peng, M.D., Ph.D., President and Head of R&D of Alpine. "Our prior preclinical studies demonstrated that the combination of ALPN-202 and a PD-1 inhibitor can be particularly advantageous, and this collaboration will greatly enable our ability to pursue this opportunity in the clinic. This study, in conjunction with NEON-1, ALPN-202's ongoing first-in-human monotherapy trial, will provide insights across a broad spectrum of cancers and lines of therapy."

    KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

    About ALPN-202

    ALPN-202 is a first-in-class, conditional CD28 costimulator and dual checkpoint inhibitor with the potential to improve upon the efficacy of combined checkpoint inhibition while limiting significant toxicities. Preclinical studies of ALPN-202 have successfully demonstrated superior efficacy in tumor models compared to checkpoint inhibition alone. NEON-1 (NCT04186637), a monotherapy study of ALPN-202 in patients with advanced malignancies, and NEON-2 (NCT04920383), a study of ALPN-202 in combination with KEYTRUDA® (pembrolizumab) in patients with advanced malignancies, are currently enrolling.

    About Alpine Immune Sciences, Inc.

    Alpine Immune Sciences, Inc. is committed to leading a new wave of immune therapeutics. With world-class research and development capabilities, a highly productive scientific platform, and a proven management team, Alpine is seeking to create first- or best-in-class multifunctional immunotherapies via unique protein engineering technologies to improve patients' lives. Alpine has entered into strategic collaborations with leading global biopharmaceutical companies and has a diverse pipeline of clinical and preclinical candidates in development. For more information, visit www.alpineimmunesciences.com. Follow @AlpineImmuneSci on Twitter and LinkedIn.

    Forward-Looking Statements

    This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include statements regarding our platform technology and potential therapies; the timing of and results from clinical trials and preclinical development activities; clinical and regulatory objectives and the timing thereof; the potential efficacy, safety profile, future development plans, addressable market, regulatory success, and commercial potential of our product candidates; the progress and potential of our other ongoing development programs; the efficacy of our clinical trial designs; anticipated enrollment in our clinical trials and the timing thereof; expectations regarding our ongoing collaborations; and our ability to successfully develop and achieve milestones in our development programs. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions and include words such as "may," "will," "should," "would," "expect," "plan," "intend," and other similar expressions, among others. These forward-looking statements are based on current assumptions that involve risks, uncertainties, and other factors that may cause actual results, events, or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: the impact of the COVID-19 pandemic on our business, research and clinical development plans and timelines and results of operations, including the impact on our clinical trial sites, collaborators, and contractors who act for or on our behalf, may be more severe and prolonged than currently anticipated; clinical trials may not demonstrate safety and efficacy of any of our product candidates; our ongoing discovery and preclinical efforts may not yield additional product candidates; our discovery-stage and preclinical programs may not advance into the clinic or result in approved products; any of our product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; we may not achieve additional milestones in our proprietary or partnered programs; the impact of competition; adverse conditions in the general domestic and global economic markets; as well as the other risks identified in our filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof and we undertake no obligation to update forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements.

    View Full Article Hide Full Article
View All Alpine Immune Sciences Inc. News